Perspective Therapeutics (CATX) EPS (Basic) (2010 - 2026)
Perspective Therapeutics' (CATX) quarterly EPS (Basic) came in at -$0.22 in Q2 2026, up 23.29% year-over-year from -$0.18 in Q2 2025, and up 19.92% quarter-over-quarter from -$0.28 in Q1 2026.
Powered by 
Analysis
Perspective Therapeutics (CATX) EPS (Basic) (2010 - 2026) Analysis & Trends
Perspective Therapeutics has disclosed EPS (Basic) across 17 years of filings, most recently posting -$0.22 for Q2 2026.
- In Q2 2026, EPS (Basic) rose 23.29% year-over-year to -$0.22; the TTM figure through Jun 2026 stood at -$0.99 (up 24.81% YoY), while the FY2025 annual figure was -$1.41, down 10.17% from the prior year.
- EPS (Basic) came in at -$0.22 for Q2 2026 at Perspective Therapeutics, up from -$0.28 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of -$0.08 in Q1 2023 to a low of -$0.87 in Q4 2023.
- Average EPS (Basic) over 5 years is -$0.35, with a median of -$0.28 recorded in 2025.
- Year-over-year, EPS (Basic) tumbled 432.44% in 2022 and jumped 61.36% in 2024.
- Over 5 years, EPS (Basic) stood at -$0.6 in 2022, then sank by 44.15% to -$0.87 in 2023, then rose by 22.65% to -$0.67 in 2024, then advanced by 22.68% to -$0.52 in 2025, then soared by 57.19% to -$0.22 in 2026.
- Per Business Quant data, the three most recent EPS (Basic) figures were -$0.22 in Q2 2026, -$0.28 in Q1 2026, and -$0.52 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 4.40 |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -8.44 |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 4.34 |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 12.62 |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 7.70 |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -1.96 |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 1.23 |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 0.66 |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -0.40 |
| 10 | Perspective Therapeutics | 361.95 Mn | 361.95 Mn | - | -0.22 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.22 |
| Mar 31, 2026 | -0.28 |
| Dec 31, 2025 | -0.52 |
| Sep 30, 2025 | -0.35 |
| Jun 30, 2025 | -0.29 |
| Mar 31, 2025 | -0.25 |
| Dec 31, 2024 | -0.67 |
| Sep 30, 2024 | -0.21 |
| Jun 30, 2024 | -0.18 |
| Mar 31, 2024 | -0.25 |
| Dec 31, 2023 | -0.87 |
| Sep 30, 2023 | -0.40 |
| Jun 30, 2023 | -0.45 |
| Mar 31, 2023 | -0.08 |
| Dec 31, 2022 | -0.60 |
| Sep 30, 2022 | -0.53 |
| Jun 30, 2022 | -0.15 |
| Mar 31, 2022 | -0.09 |
| Dec 31, 2021 | -0.11 |
| Sep 30, 2021 | -0.16 |